Conditions: Plaque Psoriasis
Keywords: cyclosporine A
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 34
Healthy volunteers: no

Brief summary:
The purpose of this study was to assess the efficacy and safety of secukinumab at Week 16 based on psoriasis area and severity index (PASI) 75 in subjects who had inadequate response to cyclosporine A.

Detailed description:

Arms:
arm 1: Participants received secukinumab 300 mg subcutaneously (s.c.) (two 150 mg injections) on Day 1 and at Weeks 1, 2, 3, 4, 8 and 12.

Interventions: intervention 1: Secukinumab (AIN457)
Intervention descriptions: intervention 1: Secukinumab was supplied as 150 mg doses, provided in 1 mL prefilled syringes.

Protocol document: